The 2019 Worldwide Market for Cancer Immunotherapy – Focus on Pharmaceutical Products & Therapeutic Indication (2018-2028): A $170+ Billion Opportunity – ResearchAndMarkets.com – Business Wire

Source: The 2019 Worldwide Market for Cancer Immunotherapy – Focus on Pharmaceutical Products & Therapeutic Indication (2018-2028): A $170+ Billion Opportunity – ResearchAndMarkets.com – Business Wire

DUBLIN–(BUSINESS WIRE)–The “Global
Cancer Immunotherapy Market: Focus on Pharmaceutical Products,
Therapeutic Indication, Competitive Landscape and Region – Analysis and
Forecast, 2018-2028” report has been added to ResearchAndMarkets.com’s
offering.

According to WHO, cancer claimed 8.8 million lives in 2015 and accounted
for almost 1 in 6 global deaths. In low- and middle-income countries,
about 70% of deaths are caused due to cancer, resulting in a significant
burden on the healthcare and economy of these countries. The treatment
of cancer is long-term and involves extensive therapies that are
expensive, and act as an economic burden on the patients and their
families. It has been estimated that global spending on cancer therapies
and supportive care drugs exceed $133 billion and is expected to
increase to $200 billion by 2022.

Cancer Immunotherapy or, immuno-oncology, is the treatment that utilizes
the body’s self-immune system to combat cancer. The immunotherapy
treatments either boost the body’s immune system against cancer or acts
as the immune system to identify the cancerous cells and destroy them.
Immunotherapy is precision (personalized) medicine that works better for
some types of cancer; however, this treatment is now used for different
types of cancer. The first immunotherapy treatment, Yervoy, was approved
and commercialized in 2011 by US-based bio-pharmaceutical company,
Bristol-Myers Squibb.

Recently with the discovery of new oncology targets and increased
knowledge about cancer, newer immunotherapy options have been
discovered. For e.g., approval of novel checkpoints (targets in the body
of a patient with cancer) inhibitors against PD-1 and PD-L1, have
revolutionized the immune-oncology market with their rapid uptake among
the patients.

The global cancer immunotherapy market was valued at $39.86 billion in
2017 and is anticipated to reach $170.7 billion by 2028.

The rising prevalence of cancer around the world and high unmet medical
needs of patients with cancer are stimulators for the growth of the
cancer immunotherapy market. In addition, the advancements in precision
medicine for immuno-oncology and rise in expenditure by pharmaceutical
companies on R&D for cancer treatments, are contributing to the rise in
demand for cancer immunotherapy as a treatment for cancer.

Based on products, the market can be sub-segmented into monoclonal
antibodies, check point inhibitors, cancer vaccine, and others. The
market for monoclonal antibodies dominates the market in terms of
revenue. The growth of the monoclonal antibodies market is accredited to
the efficacy of these targeted antibodies, rising demand for advanced
oncology medicines along with an increase in the research and
development facilities globally. However, Check Point Inhibitors exhibit
a higher growth rate as they have shown to be more efficacious and have
less toxicity as compared to other product classes. These products have
a novel mechanism of action which have revolutionized the cancer
immunotherapy market.

Based on therapeutic indication, the market can be classified into seven
major cancer types, which include breast cancer, melanoma, non-small
cell lung cancer (NSCLC), colorectal cancer, renal cell carcinoma,
gastric cancer, and others. Among the different types of cancers, breast
cancer is the leading contributor to metastatic cancer treatment market,
while the highest CAGR is expected to be registered by NSCLC during the
forecast period from 2018 to 2028.

The cancer immunotherapy market has a promising potential for growth in
the coming years. The report provides an in-depth SWOT analysis of
different key players of the market, supported by an extensive financial
summary of each company. The key players of the market are Aduro
Biotech, Inc, Amgen Inc., AstraZeneca PLC, Boehringer Ingelheim, Bristol
Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F.
Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co., Inc., Novartis AG,
Pfizer Inc., and Gilead Sciences, Inc, among others.

Topics Covered

Executive Summary

1 Market Overview
1.1 Cancer Immunotherapy
1.2 Types of Cancer
Immunotherapy

2 Market Dynamics
2.1 Drivers
2.1.1 Rising Prevalence of Cancer
2.1.2
Unmet Medical Needs of Cancer Patients
2.1.3 Rising R&D Expenditure
in the Immuno-Oncology Segment
2.1.4 Advancement of Precision
Medicine in Immuno-oncology
2.2 Restraints
2.2.1 High Cost of
Treatment
2.2.2 Adverse Effects of Immunotherapy Treatment
2.3
Opportunities
2.3.1 Development of Targeted Therapy
2.3.2
Development of Healthcare Infrastructure and Reimbursement Policies in
Emerging Economies
2.3.3 Combination Therapy

3 Competitive Landscape
3.1 Key Developmental Strategies
3.2
Market Share Analysis

4 Industry Insights
4.1 Regulatory Organizations/ Associations/
Consortiums
4.2 Patent Landscape
4.3 Regulatory Designations

5 Global Cancer Immunotherapy Market (By Product)
5.1 Monoclonal
Antibodies
5.2 Checkpoint Inhibitors
5.3 Cancer Vaccines

6 Global Cancer Immunotherapy Market (by Therapeutic Indication)
6.1
Breast Cancer
6.2 Non-Small Cell Lung Cancer (NSCLC)
6.3
Melanoma
6.4 Colorectal Cancer
6.5 Renal Cell Carcinoma
6.6
Gastric Cancer
6.7 Others

7 Global Cancer Immunotherapy Market (by Region)
7.1 North America
7.2
Europe
7.3 Asia-Pacific
7.4 Latin America
7.5
Rest-of-the-World (RoW)

8 Company Profiles
8.1 Overview
8.2 Aduro Biotech
8.3
Amgen
8.4 AstraZeneca PLC
8.5 Bristol-Myers Squibb
8.6
Celgene Corporation
8.7 DNAtrix Therapeutics
8.8 Eli Lilly and
Company
8.9 Gilead Sciences Inc.
8.10 Fate Therapeutics
8.11
F. Hoffmann La Roche
8.12 Johnson & Johnson
8.13 Merck &
Co. Inc.
8.14 Novartis AG
8.15 Pfizer Inc.
8.16 Precision
BioSciences Inc.
8.17 Iovance Biotherapeutics: Snapshot

9 Research Scope and Methodology
9.1 Scope of the Report
9.2
Global Cancer Immunotherapy Market Segmentation
9.3 Research
Methodology
9.4 Assumptions and Limitations

For more information about this report visit https://www.researchandmarkets.com/research/6fxjkt/the_2019?w=4

Published at Tue, 26 Feb 2019 15:22:00 +0000